查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1840823

CRISPR和Cas基因市场按应用、最终用户、Cas类型、递送方法和技术划分－2025-2032年全球预测

CRISPR & Cas Genes Market by Application, End User, Cas Type, Delivery Method, Technology - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，CRISPR 和 Cas 基因市场将成长至 503.6 亿美元，复合年增长率为 33.32%。

关键市场统计数据
基准年 2024 50.4亿美元
预计年份：2025年 67.4亿美元
预测年份 2032 503.6亿美元
复合年增长率 (%) 33.32%

CRISPR和Cas基因演化的简明框架以及在研究、转化和商业功能方面进行策略合作的必要性

CRISPR及其相关的Cas基因係统已从实验室工具迅速发展成为支撑现代基因编辑、诊断和治疗设计的基础平台。本文概述了CRISPR-Cas的技术发展历程，阐述了其从基础研究到应用流程的转变，以及正在重塑转化时间表的整合趋势，包括递送创新、多重编辑策略和诊断整合。在此基础上，本文解释了生物技术、生物製药、委外研发机构和学术中心的领导者为何必须使其研究策略与新兴平台的能力保持一致。

随着该领域的日趋成熟，研究重点正从概念验证性编辑转向可重复、可扩展且符合监管要求的工作流程。新型Cas变体、改进的递送方式以及配套的诊断读数降低了临床应用的门槛，同时也加剧了团队必须应对的技术和商业性复杂性。本导言深入剖析了不断变化的市场格局、考虑价格因素的供应模式、市场细分资讯以及区域性动态，旨在帮助科研、监管和商业领域的领导者做出明智的营运决策。

分子发现、递送工程、诊断融合和监管成熟如何重塑研发路径和策略重点

CRISPR和Cas系统的研究模式正因分子发现、递送工程以及与诊断和计算生物学的跨学科整合等方面的同步进展而发生变革。新型Cas效应蛋白和工程突变体的发现正在拓展分子工具箱，使以往难以触及的新标靶类型和编辑模式成为可能。同时，从非病毒奈米颗粒到改良的病毒载体和电穿孔方案等递送技术的创新，使得对编辑活性进行时空控製成为可能。

此外，诊断技术正与基因编辑平台融合，形成闭合迴路工作流程，将检测、分层和治疗更紧密地整合在一起。这种转变正在加速精准感染疾病诊断、照护现场基因筛检和原位治疗监测等应用情境的发展。法规环境也在日趋成熟，各机构发布了关于人类体细胞基因组编辑和诊断的指导意见，强调安全性、可追溯性和可重复性。因此，各机构正从单一资产计划转向以平台为导向的策略，这些策略以可扩展的生产、标准化的品质体係以及在交付、分析和临床营运方面的伙伴关係为核心。这些因素共同作用，正在改变整个生态系统中专案的规划、资金筹措和执行方式。

了解关税带来的供应链和采购压力将如何迫使 CRISPR 专案实现供应多元化、考虑本地化生产以及製定应对策略。

关税的征收会改变供应链、采购成本以及实验室和生产设施中设备和试剂的供应。就 CRISPR 和 Cas 系统而言，关键投入包括专用酵素和试剂、用于细胞操作和定序的精密设备，以及用于生产递送载体的组件，例如脂质奈米颗粒化学品和病毒载体生产耗材。当关税主导的成本压力改变这些投入的经济效益时，各组织会优先考虑供应的连续性、寻找合格的替代供应商，或将部分供应链本地化，以确保专案按时完成。

在营运方面，企业领导者奖励重新评估库存策略，投资于冗余或地理分散的供应商，并加快供应商资格认证通讯协定。对于转化医学计画而言，关键物资的延迟或供应不稳定可能导致临床前研究週期延长和临床试验延期，从而错失研发管线中的机会。贸易政策摩擦也会影响细胞处理和高通量定序平台等高价值资本设备的策略采购决策，促使企业重新谈判服务等级协定或寻求翻新或国产替代方案。总之，关税的影响不仅体现在直接的成本压力上，也将成为研发和生产营运中供应弹性、在地化生产和供应商多元化的策略驱动因素。

将应用、最终用户、废弃物类型、供应链和技术路径连结起来的多维度细分智能，可指导投资和营运选择。

精细化的细分视角为转换和商业性路径的优先排序提供了切实可行的依据。基于应用领域，研究团队和商业策略师应区分农业生物技术、动物模型开发、诊断、基因编辑和基因治疗的投资，并认识到诊断可进一步细分为疾病检测和基因筛检，基因编辑可细分为研究和治疗应用。这种应用领域的层级划分凸显了监管复杂性、报销途径和见效时间的显着差异。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 碱基编辑技术的进步正在推动精准基因治疗，并减少脱靶效应。
  • CRISPR基因编辑平台在治疗遗传疾病的商业性化应用已进入临床试验阶段。
  • 新兴的体内递送载体优化了CRISPR Cas蛋白复合物，使其具有目标组织特异性。
  • 生技公司与合约研究组织建立策略伙伴关係关係，以加速 CRISPR筛检服务
  • 正在不断改进的法规结构旨在解决人类生殖细胞基因编辑试验中的伦理问题

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. CRISPR和Cas基因市场按应用领域划分

  • 农业生物技术
  • 动物模型开发
  • 诊断
    • 疾病检测
    • 基因检测
  • 基因编辑
    • 研究用途
    • 治疗用途
  • 基因治疗

9. 按最终使用者分類的 CRISPR 和 Cas 基因市场

  • 生技公司
    • 已成立的公司
    • Start-Ups
  • 合约研究机构
    • 临床服务
    • 临床前服务
  • 製药公司
    • 生物製药公司
    • 大型製药公司
  • 研究所

10. CRISPR 和 Cas 基因市场（按 CAS 类型划分）

  • Cas12
  • Cas13
  • Cas14
  • Cas9

11. CRISPR 和 Cas 基因市场按递送方式划分

  • 电穿孔
  • 脂质体转染
  • 显微注射
  • 奈米颗粒递送
    • 脂质奈米颗粒
    • 聚合物奈米粒子
  • 病毒载体
    • 腺结合病毒
    • 腺病毒
    • 慢病毒

12. CRISPR 和 Cas 基因市场（按技术划分）

  • 体外
    • 细胞株工程
    • 初代细胞的修饰
  • 体内
    • 临床试验
    • 临床前模型

13. CRISPR和Cas基因市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 CRISPR和Cas基因市场（按群体划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国 CRISPR 和 Cas 基因市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Merck KGaA
    • QIAGEN NV
    • Agilent Technologies, Inc.
    • Illumina, Inc.
    • PerkinElmer, Inc.
    • GenScript Biotech Corporation
    • Bio-Rad Laboratories, Inc.
    • Synthego Corporation
Product Code: MRR-5642D503D83C

The CRISPR & Cas Genes Market is projected to grow by USD 50.36 billion at a CAGR of 33.32% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.04 billion
Estimated Year [2025] USD 6.74 billion
Forecast Year [2032] USD 50.36 billion
CAGR (%) 33.32%

A concise framing of CRISPR and Cas gene evolution and the imperative for strategic alignment across research, translational, and commercialization functions

CRISPR and its associated Cas gene systems have rapidly evolved from a laboratory tool into a foundational platform that underpins modern gene editing, diagnostics, and therapeutic design. This introduction synthesizes the technical lineage of CRISPR-Cas, its transition from basic research into applied pipelines, and the converging trends-such as delivery innovation, multiplex editing strategies, and diagnostic integration-that are reshaping translational timelines. In doing so, it frames why organizational leaders across biotechnology, biopharma, contract research organizations, and academic centers must align research strategy with emergent platform capabilities.

As the field matures, emphasis is shifting from proof-of-concept edits to reproducible, scalable, and regulatory-compliant workflows. Novel Cas variants, improved delivery modalities, and paired diagnostic-readouts have collectively lowered barriers to clinical translation while simultaneously amplifying the technical and commercial complexity teams must navigate. This introduction therefore sets the scene for deeper sections that address landscape shifts, tariff-driven supply considerations, segmentation intelligence, and region-specific dynamics, all of which inform operational choices for science, regulatory, and commercial leaders.

How molecular discovery, delivery engineering, diagnostic convergence, and regulatory maturation are collectively reshaping development pathways and strategic priorities

The landscape for CRISPR and Cas systems is undergoing transformative shifts driven by parallel advances in molecular discovery, delivery engineering, and cross-disciplinary integration with diagnostics and computational biology. Discovery of alternative Cas effectors and engineered variants is expanding the molecular toolbox, enabling new target classes and editing modalities that were previously inaccessible. Concomitantly, delivery innovations-ranging from nonviral nanoparticles to refined viral vectors and electroporation protocols-are enabling spatial and temporal control over editing activity, which in turn reduces off-target risk and enhances therapeutic index.

Translationally, diagnostics are converging with editing platforms to create closed-loop workflows where detection, stratification, and treatment are more tightly coupled. This shift is accelerating use cases in precision infectious disease diagnostics, point-of-care genetic screening, and in situ therapeutic monitoring. The regulatory environment is also maturing, with agencies publishing guidance on human somatic genome editing and diagnostics that emphasize safety, traceability, and reproducibility. As a result, organizations are moving from single-asset projects to platform-oriented strategies that center on scalable manufacturing, standardized quality systems, and partnerships across delivery, analytics, and clinical operations. Together, these dynamics are changing how programs are designed, funded, and executed across the ecosystem.

Understanding how tariff-driven supply chain and procurement pressures compel supply diversification, local manufacturing considerations, and resilience strategies for CRISPR programs

The introduction of tariffs can alter supply chains, procurement costs, and the cadence of equipment and reagent availability for laboratories and manufacturing facilities. In the context of CRISPR and Cas systems, key inputs include specialized enzymes and reagents, precision instrumentation for cell manipulation and sequencing, and components for manufacturing delivery modalities such as lipid nanoparticle chemistries and viral vector production consumables. When tariff-driven cost pressure changes the economics of these inputs, organizations respond by prioritizing supply continuity, qualifying alternative suppliers, or localizing portions of their supply base to preserve program timelines.

Operationally, leaders are incentivized to reassess inventory strategies, invest in redundant or regionally distributed suppliers, and accelerate vendor qualification protocols. For translational programs, any delay or variance in critical supplies can cascade into longer preclinical timelines or deferred clinical activities, creating opportunity costs for pipelines. Trade policy friction also influences strategic sourcing decisions for high-value capital equipment such as cell processing and high-throughput sequencing platforms, prompting organizations to renegotiate service-level agreements or explore refurbished and domestically produced alternatives. In sum, tariff impacts manifest not only as direct cost pressures but as strategic drivers of supply resilience, local manufacturing consideration, and supplier diversification across R&D and manufacturing operations.

Multidimensional segmentation intelligence linking application, end user, Cas type, delivery modality, and technology pathways to guide investment and operational choices

A granular segmentation view provides practical levers for prioritization across translational and commercial pathways. Based on Application, research teams and commercial strategists must differentiate investments across Agricultural Biotechnology, Animal Model Development, Diagnostics, Gene Editing, and Gene Therapy, recognizing that Diagnostics is further divided into Disease Detection and Genetic Screening while Gene Editing splits into Research Applications and Therapeutic Applications. This layered application segmentation clarifies where regulatory complexity, reimbursement pathways, and time-to-impact differ markedly.

Based on End User, the ecosystem dynamics change depending on the buyer and operator: Biotechnology Companies, Contract Research Organizations, Pharmaceutical Companies, and Research Institutes each bring different procurement rhythms and risk tolerances. Within this, Biotechnology Companies can be viewed through the lens of Established Firms versus Startups; Contract Research Organizations separate into Clinical Services and Preclinical Services; and Pharmaceutical Companies include both Biopharma Firms and Large Pharma. These distinctions matter for partner selection, contracting models, and commercialization timelines.

Based on Cas Type, applications track to molecular capability: Cas12, Cas13, Cas14, and Cas9 each have distinct biochemical properties and target class compatibilities, which influence assay design, therapeutic targeting, and IP considerations. Based on Delivery Method, practical trade-offs exist among Electroporation, Liposome Transfection, Microinjection, Nanoparticle Delivery, and Viral Vector, with Nanoparticle Delivery subdividing into Lipid Nanoparticles and Polymer Nanoparticles and Viral Vector further subdividing into Adeno Associated Virus, Adenovirus, and Lentivirus. Each delivery option requires different manufacturing capabilities, regulatory dossiers, and safety-monitoring frameworks.

Finally, Based on Technology, programs diverge along Ex Vivo and In Vivo pathways. Ex Vivo work is refined into Cell Line Engineering and Primary Cell Modification, which often emphasizes process control and closed-system manufacturing, while In Vivo approaches encompass Clinical Trials and Preclinical Models and prioritize biodistribution, immunogenicity, and delivery optimization. Together, these segmentation layers create a multidimensional view that helps leaders prioritize where to allocate capital, how to structure partnerships, and which operational capabilities to develop internally.

Regional development, regulatory variation, and investment dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific shaping adoption and operational strategy

Regional dynamics shape how CRISPR and Cas gene technologies are developed, funded, and adopted, and understanding geographic nuances helps allocate commercial and operational resources effectively. In the Americas, public and private investment ecosystems are robust and often support high-risk translational projects, with strong venture capital activity and major clinical development centers that accelerate first-in-human studies. This region tends to lead in platform startups and partnering transactions that bridge academic innovation and commercial scaling, while also facing concentrated regulatory scrutiny and payer dynamics that influence clinical development strategies.

Europe, Middle East & Africa present a heterogeneous regulatory and funding landscape where collaborative research networks, strong academic hubs, and strategic national initiatives coexist with varied reimbursement systems and approval timelines. Regional centers of excellence emphasize translational rigor and early patient engagement, and cross-border collaborations are common to access patient cohorts and diverse expertise. Concurrently, nations within the region prioritize different technology pathways based on local public health needs and industrial policy.

Asia-Pacific exhibits rapid adoption driven by significant public R&D investment, expanding domestic biopharma capability, and a growing manufacturing base for biologics and delivery systems. Several markets are actively building clinical trial capacity and local regulatory clarity to attract global development programs. As a result, Asia-Pacific is increasingly important for scaling manufacturing, accessing diverse patient populations, and sourcing specialized reagents and components, making it an essential region for global operational planning.

How platform breadth, delivery capability, clinical execution, manufacturing scale, and strategic partnerships define competitive advantage and partnership opportunities

Company strategies in the CRISPR and Cas gene ecosystem are converging around a set of differentiators: platform breadth, delivery expertise, clinical execution capability, manufacturing scale, and strategic partnerships. Platform breadth is valuable for firms that aim to address multiple therapeutic areas or diagnostic applications, because it enables asset-level diversification and cross-program learning. Delivery expertise has become a critical competitive moat; organizations that can reliably deliver editing machinery with favorable safety profiles command a higher strategic premium and greater ability to partner with large clinical developers.

Clinical execution and regulatory navigation distinguish companies that successfully transition from discovery-stage programs to late-stage development. Firms investing early in manufacturing and quality systems shorten the timeline from clinical proof-of-concept to commercial readiness. Strategic partnerships, whether they are co-development agreements, technology licensing, or manufacturing collaborations, are central to scale-up strategies and risk-sharing. Across the ecosystem, successful companies combine deep technical expertise with operational dexterity, aligning R&D pipelines to pragmatic commercialization routes and forming partnerships that address gaps in delivery, analytics, and regulatory affairs.

Targeted operational and partnership actions to de-risk pipelines, scale manufacturing modularity, and accelerate regulated translation of CRISPR and Cas gene initiatives

Industry leaders should adopt a set of actionable priorities that translate insight into measurable progress. First, prioritize supplier and delivery redundancy by qualifying alternative reagent and equipment suppliers, and by validating multiple delivery approaches to de-risk program timelines. Second, invest in modular manufacturing and quality systems that can be repurposed across ex vivo and in vivo programs to maximize capital efficiency while meeting evolving regulatory expectations. Third, align early regulatory engagement with robust safety and monitoring plans to streamline translational pathways and reduce later-stage attrition.

In parallel, pursue strategic collaborations that complement internal capabilities: partner with specialized CDMOs and delivery technology providers to accelerate manufacturing scale, and form data partnerships to enhance diagnostic and stratification strategies. Build internal capabilities in analytical characterization and bioinformatics to optimize editing specificity and to support regulatory dossiers. Finally, develop market-access playbooks that integrate diagnostic companion strategies, payer engagement, and clear value narratives to support commercialization decisions. These actions create a defensible, pragmatic path from innovation to sustained clinical and commercial impact.

A mixed-methods research approach combining primary interviews, literature synthesis, regulatory analysis, and scenario testing to validate strategic conclusions and assumptions

The research methodology underpinning this analysis blends primary and secondary intelligence with rigorous synthesis to ensure actionable reliability. Primary inputs include structured interviews with technical leaders across biotech, contract research organizations, pharmaceutical development teams, and academic investigators, supplemented by direct input from manufacturing and regulatory professionals. Secondary inputs incorporate peer-reviewed literature, publicly available regulatory guidance, patent analysis, and clinical trial registry data to triangulate program trajectories and technology adoption patterns.

Analytical approaches applied include technology readiness assessments, supply chain stress-testing, and scenario planning that incorporates policy and trade variables. Where appropriate, cross-validation was used to reconcile divergent perspectives, ensuring conclusions reflect consensus where it exists and clearly flag areas of uncertainty. This mixed-method approach provides executives with a robust base of evidence to inform strategy, while also highlighting critical assumptions and sensitivity points that merit ongoing monitoring.

Synthesis of platform maturation, supply resilience, delivery innovation, and partnership imperatives to convert CRISPR science into durable clinical and commercial outcomes

In conclusion, CRISPR and Cas gene systems are transitioning from compartmentalized laboratory methods to integrated platforms that span diagnostics, therapeutics, and agriculture. Key inflection points include maturation of delivery technologies, the emergence of multiple Cas effectors with complementary capabilities, and an evolving regulatory environment that emphasizes reproducibility and safety. These dynamics create both opportunity and complexity: organizations that invest in diversified delivery strategies, resilient supply chains, and targeted partnerships will be best positioned to capture translational value.

Looking ahead, executives should balance near-term operational resilience with longer-term platform investments. Prioritizing modular manufacturing, regulatory foresight, and cross-sector partnerships will enable organizations to convert technical innovation into clinical and commercial outcomes. Sustained progress will depend on disciplined execution, transparent data practices, and continued investment in delivery and analytics capabilities that together reduce technical risk and improve patient and market impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in base editing technologies driving precision gene therapies with reduced off-target effects
  • 5.2. Commercial adoption of CRISPR prime editing platforms for treatment of genetic disorders in clinical pipelines
  • 5.3. Emergence of in vivo delivery vehicles optimizing CRISPR Cas protein complexes for targeted tissue specificity
  • 5.4. Strategic partnerships between biotech firms and contract research organizations to accelerate CRISPR screening services
  • 5.5. Regulatory frameworks evolving to address ethical considerations around human germline gene editing trials

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. CRISPR & Cas Genes Market, by Application

  • 8.1. Agricultural Biotechnology
  • 8.2. Animal Model Development
  • 8.3. Diagnostics
    • 8.3.1. Disease Detection
    • 8.3.2. Genetic Screening
  • 8.4. Gene Editing
    • 8.4.1. Research Applications
    • 8.4.2. Therapeutic Applications
  • 8.5. Gene Therapy

9. CRISPR & Cas Genes Market, by End User

  • 9.1. Biotechnology Companies
    • 9.1.1. Established Firms
    • 9.1.2. Startups
  • 9.2. Contract Research Organizations
    • 9.2.1. Clinical Services
    • 9.2.2. Preclinical Services
  • 9.3. Pharmaceutical Companies
    • 9.3.1. Biopharma Firms
    • 9.3.2. Large Pharma
  • 9.4. Research Institutes

10. CRISPR & Cas Genes Market, by Cas Type

  • 10.1. Cas12
  • 10.2. Cas13
  • 10.3. Cas14
  • 10.4. Cas9

11. CRISPR & Cas Genes Market, by Delivery Method

  • 11.1. Electroporation
  • 11.2. Liposome Transfection
  • 11.3. Microinjection
  • 11.4. Nanoparticle Delivery
    • 11.4.1. Lipid Nanoparticles
    • 11.4.2. Polymer Nanoparticles
  • 11.5. Viral Vector
    • 11.5.1. Adeno Associated Virus
    • 11.5.2. Adenovirus
    • 11.5.3. Lentivirus

12. CRISPR & Cas Genes Market, by Technology

  • 12.1. Ex Vivo
    • 12.1.1. Cell Line Engineering
    • 12.1.2. Primary Cell Modification
  • 12.2. In Vivo
    • 12.2.1. Clinical Trials
    • 12.2.2. Preclinical Models

13. CRISPR & Cas Genes Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. CRISPR & Cas Genes Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. CRISPR & Cas Genes Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Thermo Fisher Scientific Inc.
    • 16.3.2. Danaher Corporation
    • 16.3.3. Merck KGaA
    • 16.3.4. QIAGEN N.V.
    • 16.3.5. Agilent Technologies, Inc.
    • 16.3.6. Illumina, Inc.
    • 16.3.7. PerkinElmer, Inc.
    • 16.3.8. GenScript Biotech Corporation
    • 16.3.9. Bio-Rad Laboratories, Inc.
    • 16.3.10. Synthego Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL CRISPR & CAS GENES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CRISPR & CAS GENES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. CRISPR & CAS GENES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. CRISPR & CAS GENES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CRISPR & CAS GENES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CRISPR & CAS GENES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CRISPR & CAS GENES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY AGRICULTURAL BIOTECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY AGRICULTURAL BIOTECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY AGRICULTURAL BIOTECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY AGRICULTURAL BIOTECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY AGRICULTURAL BIOTECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY AGRICULTURAL BIOTECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ANIMAL MODEL DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ANIMAL MODEL DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ANIMAL MODEL DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ANIMAL MODEL DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ANIMAL MODEL DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ANIMAL MODEL DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DISEASE DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DISEASE DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DISEASE DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DISEASE DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DISEASE DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DISEASE DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENETIC SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENETIC SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENETIC SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENETIC SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENETIC SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENETIC SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY RESEARCH APPLICATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY RESEARCH APPLICATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY RESEARCH APPLICATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY RESEARCH APPLICATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY THERAPEUTIC APPLICATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ESTABLISHED FIRMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ESTABLISHED FIRMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ESTABLISHED FIRMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ESTABLISHED FIRMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ESTABLISHED FIRMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ESTABLISHED FIRMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY STARTUPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY STARTUPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY STARTUPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY STARTUPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY STARTUPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY STARTUPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CLINICAL SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CLINICAL SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CLINICAL SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CLINICAL SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CLINICAL SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CLINICAL SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRECLINICAL SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRECLINICAL SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRECLINICAL SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRECLINICAL SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRECLINICAL SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRECLINICAL SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY BIOPHARMA FIRMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY BIOPHARMA FIRMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY BIOPHARMA FIRMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY BIOPHARMA FIRMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY BIOPHARMA FIRMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY BIOPHARMA FIRMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LARGE PHARMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LARGE PHARMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS12, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS12, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS12, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS12, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS12, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS12, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS13, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS13, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS13, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS13, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS13, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS13, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS14, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS14, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS14, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS14, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS14, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS14, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS9, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS9, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS9, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS9, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS9, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS9, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ELECTROPORATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LIPOSOME TRANSFECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LIPOSOME TRANSFECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LIPOSOME TRANSFECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LIPOSOME TRANSFECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LIPOSOME TRANSFECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LIPOSOME TRANSFECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY MICROINJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY MICROINJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY MICROINJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY MICROINJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY MICROINJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY MICROINJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY POLYMER NANOPARTICLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY POLYMER NANOPARTICLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY POLYMER NANOPARTICLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY POLYMER NANOPARTICLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY POLYMER NANOPARTICLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY POLYMER NANOPARTICLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ADENOVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LENTIVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LENTIVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LENTIVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LENTIVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LENTIVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY LENTIVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CELL LINE ENGINEERING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CELL LINE ENGINEERING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CELL LINE ENGINEERING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CELL LINE ENGINEERING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CELL LINE ENGINEERING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CELL LINE ENGINEERING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRIMARY CELL MODIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRIMARY CELL MODIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRIMARY CELL MODIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRIMARY CELL MODIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRIMARY CELL MODIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRIMARY CELL MODIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CLINICAL TRIALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CLINICAL TRIALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CLINICAL TRIALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CLINICAL TRIALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRECLINICAL MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRECLINICAL MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRECLINICAL MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRECLINICAL MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRECLINICAL MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY PRECLINICAL MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2025-2032 (USD MILLION)
  • TABLE 297. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2024 (USD MILLION)
  • TABLE 298. AMERICAS CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
  • TABLE 306. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2025-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 308. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 310. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 311. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2024 (USD MILLION)
  • TABLE 312. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2025-2032 (USD MILLION)
  • TABLE 313. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 314. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 315. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2025-2032 (USD MILLION)
  • TABLE 317. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 318. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 319. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2024 (USD MILLION)
  • TABLE 320. NORTH AMERICA CRI